Long acting GLP-1 receptor agonist (injectable)
Albiglutide 4 mg injection once weekly
ALBI_SC_4MG_QW
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.08 (0.00 to 0.82) | 0.92 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.91 (0.28 to 2.36) | 0.78 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.10 (0.00 to 1.17) | 0.94 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.07 (0.34 to 2.79) | 0.66 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.11 (0.09 to 7.02) | 0.59 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.95 (0.06 to 15.36) | 0.45 |